Cargando…

Molecular characterization of renal cell carcinoma tumors from a phase III anti-angiogenic adjuvant therapy trial

Multigene assays can provide insight into key biological processes and prognostic information to guide development and selection of adjuvant cancer therapy. We report a comprehensive genomic and transcriptomic analysis of tumor samples from 171 patients at high risk for recurrent renal cell carcinom...

Descripción completa

Detalles Bibliográficos
Autores principales:	Motzer, Robert J., Martini, Jean-François, Mu, Xinmeng J., Staehler, Michael, George, Daniel J., Valota, Olga, Lin, Xun, Pandha, Hardev S., Ching, Keith A., Ravaud, Alain
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9550765/ https://www.ncbi.nlm.nih.gov/pubmed/36216827 http://dx.doi.org/10.1038/s41467-022-33555-8

Ejemplares similares

Exploratory analysis of the platelet-to-lymphocyte ratio prognostic value in the adjuvant renal cell cancer setting
por: Patel, Anup, et al.
Publicado: (2020)

Adjuvant sunitinib in patients with high-risk renal cell carcinoma: safety, therapy management, and patient-reported outcomes in the S-TRAC trial
por: Staehler, M, et al.
Publicado: (2018)

A case for the use of receiver operating characteristic analysis of potential clinical efficacy biomarkers in advanced renal cell carcinoma
por: English, Patricia A, et al.
Publicado: (2016)

Angiogenic and immunomodulatory biomarkers in axitinib-treated patients with advanced renal cell carcinoma
por: Murphy, Danielle A, et al.
Publicado: (2020)

Investigation of novel circulating proteins, germ line single-nucleotide polymorphisms, and molecular tumor markers as potential efficacy biomarkers of first-line sunitinib therapy for advanced renal cell carcinoma
por: Motzer, Robert J., et al.
Publicado: (2014)

Induction of trismus by sunitinib and pazopanib in metastatic renal cell carcinoma
por: Iyer, Ridhima, et al.
Publicado: (2017)

Axitinib versus placebo as an adjuvant treatment of renal cell carcinoma: results from the phase III, randomized ATLAS trial
por: Gross-Goupil, M, et al.
Publicado: (2018)

Downstream of the HOX genes: Explaining conflicting tumour suppressor and oncogenic functions in cancer
por: Morgan, Richard, et al.
Publicado: (2022)

Axitinib versus sorafenib in advanced renal cell carcinoma: subanalyses by prior therapy from a randomised phase III trial
por: Escudier, B, et al.
Publicado: (2014)

Combinations of Anti-Angiogenic Agents and Immune Checkpoint Inhibitors in Renal Cell Carcinoma: Best Option?
por: Granet-Vaissiere, Estelle, et al.
Publicado: (2023)

Rationale and design of the POLEM trial: avelumab plus fluoropyrimidine-based chemotherapy as adjuvant treatment for stage III mismatch repair deficient or POLE exonuclease domain mutant colon cancer: a phase III randomised study
por: Lau, David, et al.
Publicado: (2020)

Essential Oncology for Health Professionals
por: Pandha, Hardev, et al.
Publicado: (1995)

PBX3 in Cancer
por: Morgan, Richard, et al.
Publicado: (2020)

Kinase Regulation of HOX Transcription Factors
por: Primon, Monika, et al.
Publicado: (2019)

Targeting HOX/PBX dimers in cancer
por: Morgan, Richard, et al.
Publicado: (2017)

Calcium insensitivity of FA-6, a cell line derived from a pancreatic cancer associated with humoral hypercalcemia, is mediated by the significantly reduced expression of the Calcium Sensitive Receptor transduction component p38 MAPK
por: Morgan, Richard, et al.
Publicado: (2006)

Patient-reported outcomes for axitinib vs sorafenib in metastatic renal cell carcinoma: phase III (AXIS) trial
por: Cella, D, et al.
Publicado: (2013)

Summary of Research: Adjuvant Nivolumab Plus Ipilimumab Versus Placebo for Localized Renal Cell Carcinoma After Nephrectomy (CheckMate 914): A Double-Blind, Randomized, Phase 3 Trial
por: Motzer, Robert J., et al.
Publicado: (2023)

Basaloid carcinoma of the prostate: A literature review with case report
por: Tuan, Jeffrey, et al.
Publicado: (2012)

Activation and Genetic Modification of Human Monocyte-Derived Dendritic Cells using Attenuated Salmonella typhimurium
por: Michael, Agnieszka, et al.
Publicado: (2010)

Modifying the Non-muscle Invasive Bladder Cancer Immune Microenvironment for Optimal Therapeutic Response
por: Annels, Nicola E., et al.
Publicado: (2020)

Targeting HOX and PBX transcription factors in ovarian cancer
por: Morgan, Richard, et al.
Publicado: (2010)

Phase I/II storm study: Intravenous delivery of a novel oncolytic immunotherapy agent, Coxsackievirus A21, in advanced cancer patients
por: Pandha, Hardev, et al.
Publicado: (2015)

Q-TWiST analysis to estimate overall benefit for patients with metastatic renal cell carcinoma treated in a phase III trial of sunitinib vs interferon-α
por: Patil, S, et al.
Publicado: (2012)

Decrease of Pro-Angiogenic Monocytes Predicts Clinical Response to Anti-Angiogenic Treatment in Patients with Metastatic Renal Cell Carcinoma
por: Oudard, Stephane, et al.
Publicado: (2021)

The Hitchhiker's Guide to Virotherapy
por: Donnelly, Oliver, et al.
Publicado: (2012)

Breaking androgen receptor addiction of prostate cancer by targeting different functional domains in the treatment of advanced disease
por: Maylin, Zoe R, et al.
Publicado: (2021)

Oncolytic Viruses: Do They Have a Role in Anti-Cancer Therapy?
por: Prestwich, Robin J, et al.
Publicado: (2008)

Health-related quality of life in patients with metastatic renal cell carcinoma treated with sunitinib vs interferon-α in a phase III trial: final results and geographical analysis
por: Cella, D, et al.
Publicado: (2010)

Axitinib: A Review of its Safety and Efficacy in the Treatment of Adults with Advanced Renal Cell Carcinoma
por: Gross-Goupil, Marine, et al.
Publicado: (2013)

Angiogenic Factors and Renal Disease in Pregnancy
por: Rhee, Julie S., et al.
Publicado: (2011)

Hypertension among patients with renal cell carcinoma receiving axitinib or sorafenib: analysis from the randomized phase III AXIS trial
por: Rini, Brian I., et al.
Publicado: (2014)

Autologous dendritic cell immunotherapy (DCVAC/PCa) added to docetaxel chemotherapy in a Phase III trial (viable) in men with advanced (mCRPC) prostate cancer
por: Beer, Tomasz M, et al.
Publicado: (2015)

MiRNAs as Anti-Angiogenic Adjuvant Therapy in Cancer: Synopsis and Potential
por: Lahooti, Behnaz, et al.
Publicado: (2021)

Prospective Cardiovascular Surveillance of Immune Checkpoint Inhibitor–Based Combination Therapy in Patients With Advanced Renal Cell Cancer: Data From the Phase III JAVELIN Renal 101 Trial
por: Rini, Brian I., et al.
Publicado: (2022)

Targeting HOX transcription factors in prostate cancer
por: Morgan, Richard, et al.
Publicado: (2014)

Cancer immunotherapy via combining oncolytic virotherapy with chemotherapy: recent advances
por: Simpson, Guy R, et al.
Publicado: (2016)

Membrane insertion and secretion of the Engrailed-2 (EN2) transcription factor by prostate cancer cells may induce antiviral activity in the stroma
por: Punia, Natasha, et al.
Publicado: (2019)

Inhibition of angiogenic and non-angiogenic targets by sorafenib in renal cell carcinoma (RCC) in a RCC xenograft model
por: Yuen, J S P, et al.
Publicado: (2011)

Expression of RNA interference triggers from an oncolytic herpes simplex virus results in specific silencing in tumour cells in vitro and tumours in vivo
por: Anesti, Anna-Maria, et al.
Publicado: (2010)

Cannot write session to /tmp/vufind_sessions/sess_hr97ghr41iee97m9u9u26v8s67